Membranous nephropathy: pathogenesis and treatments

Abstract

Membranous nephropathy (MN), an autoimmune disease, can manifest at any age and is among the most common causes of nephrotic syndrome in adults. In 80% of cases, the specific etiology of MN remains unknown, while the remaining cases are linked to drug use or underlying conditions like systemic lupus erythematosus, hepatitis B virus, or malignancy. Although about one-third of patients may achieve spontaneous complete or partial remission with conservative management, another third face an elevated risk of disease progression, potentially leading to end-stage renal disease within 10 years. The identification of phospholipase A2 receptor as the primary target antigen in MN has brought about a significant shift in disease management and monitoring. This review explores recent advancements in the pathophysiology of MN, encompassing pathogenesis, clinical presentations, diagnostic criteria, treatment options, and prognosis, with a focus on emerging developments in pathogenesis and therapeutic strategies aimed at halting disease progression. By synthesizing the latest research findings and clinical insights, this review seeks to contribute to the ongoing efforts to enhance our understanding and management of this challenging autoimmune disorder.

Keywords

antigenic epitope / HLA / kidney pathogenesis / membranous nephropathy / PLA2R

References

1	A Alok, A Yadav. Membranous Nephropathy. StatPearls. StatPearls Publishing; 2024.
2	P Ronco, L Beck, H Debiec, et al. Membranous nephropathy. Nat Rev Dis Primer. 2021;7(1):69.
3	W Heymann, DB Hackel, S Harwood, SG Wilson, JL Hunter. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. 1951. J Am Soc Nephrol. 2000;11(1):183-188.
4	AG Wasserstein. Membranous glomerulonephritis. J Am Soc Nephrol. 1997;8(4):664-674.
5	V Tesar, Z Hruskova. Autoantibodies in the diagnosis, monitoring, and treatment of membranous nephropathy. Front Immunol. 2021;12:593288.
6	KC Keri, S Blumenthal, V Kulkarni, L Beck, T Chongkrairatanakul. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J. 2019;95:23-31.
7	LJ Wells, ET Bell. Functioning of the fetal kidney as reflected by stillborn infants with hydroureter and hydronephrosis. Arch Pathol. 1946;42:274-276.
8	DB Jones. Nephrotic glomerulonephritis. Am J Pathol. 1957;33(2):313-329.
9	F Vendemia, L Gesualdo, FP Schena, G D'Amico. Renal Immunopathology Study Group of the Italian Society of Nephrology. Epidemiology of primary glomerulonephritis in the elderly. J Nephrol. 2001;14(5):340-352. from the Italian Registry of Renal Biopsy.
10	JH Hou, HX Zhu, ML Zhou, et al. Changes in the spectrum of kidney diseases: an analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China. Kidney Dis. 2018;4(1):10-19.
11	R Hu, S Quan, Y Wang, et al. Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases. Sci Rep. 2020;10(1):10994.
12	L Zhang, H Wang, J Long, et al. China kidney disease network (CK-NET) 2014 annual data report. Am J Kidney Dis. 2017;69(6S2):A4.
13	I Rychlik, E Jancova, V Tesar, et al. The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994–2000. Nephrol Dial Transplant. 2004;19(12):3040-3049.
14	SL Hogan, KE Muller, JC Jennette, RJ Falk. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25(6):862-875.
15	R Glassock. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003;23(4):324-332.
16	HYG Choung, B Goldman. Segmental membranous nephropathy. Clin Exp Nephrol. 2021;25(7):700-707.
17	L Alsharhan, LH Beck. Membranous nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;77(3):440-453.
18	LH Beck, RGB Bonegio, G Lambeau, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21.
19	NM Tomas, E Hoxha, AT Reinicke, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest. 2016;126(7):2519-2532.
20	J Wang, Z Cui, J Lu, et al. Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642-1651.
21	MR Hua, YL Zhao, JZ Yang, L Zou, YY Zhao, X Li. Membranous nephropathy: mechanistic insights and therapeutic perspectives. Int Immunopharmacol. 2023;120:110317.
22	Y Radhakrishnan, L Zand, S Sethi, FC Fervenza. Membranous Nephropathy Treatment Standard. Nephrol Dial Transplant. 2024;39(3):403-413.
23	BYF So, DYH Yap, TM Chan. B cells in primary membranous nephropathy: escape from immune tolerance and implications for patient management. Int J Mol Sci. 2021;22(24):13560.
24	MA Podestà, M Trillini, V Portalupi, et al. Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series. Am J Kidney Dis. 2024;83(3):340-349.
25	T Stehlé, P Grimbert, P Remy, A Moktefi, V Audard. Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression. Kidney Int. 2022;101(2):416-418.
26	A Schieppati, L Mosconi, A Perna, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329(2):85-89.
27	V Jha, A Ganguli, TK Saha, et al. Controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899-1904.
28	JE Rojas-Rivera, A Ortiz, FC Fervenza. Novel treatments paradigms: membranous nephropathy. Kidney Int Rep. 2023;8(3):419-431.
29	A Suárez-Fueyo, SJ Bradley, D Klatzmann, GC Tsokos. T cells and autoimmune kidney disease. Nat Rev Nephrol. 2017;13(6):329-343.
30	H Debiec, V Guigonis, B Mougenot, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002;346(26):2053-2060.
31	AE van de Logt, M Fresquet, JF Wetzels, P Brenchley. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019;96(6):1292-1302.
32	P Ancian, G Lambeau, MG Mattéi, M Lazdunski. The human 180-kDa receptor for secretory phospholipases A2. J Biol Chem. 1995;270(15):8963-8970.
33	T Wiech, RAK Stahl, E Hoxha. Diagnostic role of renal biopsy in PLA2R1-antibody-positive patients with nephrotic syndrome. Mod Pathol. 2019;32(9):1320-1328.
34	G Lambeau. Receptors for a growing family of secreted phospholipases A2. Trends Pharmacol Sci. 1999;20(4):162-170.
35	LH Beck, DJ Salant. Refining our understanding of the PLA2R-antibody response in primary membranous nephropathy: looking forward, looking back. J Am Soc Nephrol. 2020;31(1):8-11.
36	Y Dong, L Cao, H Tang, X Shi, Y He. Structure of human M-type phospholipase A2 receptor revealed by cryo-electron microscopy. J Mol Biol. 2017;429(24):3825-3835.
37	B Seitz-Polski, G Dolla, C Payré, et al. Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy. J Am Soc Nephrol. 2016;27(5):1517-1533.
38	J Joana, B Vesna, D Guillaume. From new epitope identification to personalized medicine in PLA2R1-related membranous nephropathy. Nephrol Dialysis Transplant. 2019(1):34. gfz101.SaO027.
39	Z Hu, Y Wang, C Cheng, Y He. Structural basis of the pH-dependent conformational change of the N-terminal region of human mannose receptor/CD206. J Struct Biol. 2019;208(3):107384.
40	H Tang, R Zhu, M Waldman, Q Zhu. Structural determinants of the dominant conformational epitopes of phospholipase A2 receptor in primary membranous nephropathy. J Biol Chem. 2022;298(3):101605.
41	XD Zhang, CX Lin, Z Cui, et al. Mapping the T cell epitopes of the M-type transmembrane phospholipase A2 receptor in primary membranous nephropathy. Kidney Int. 2023;103(3):580-592.
42	F Zhang, S Yao, M Zhang, J Yuan, X Chen, B Zhou. Roles of circulating soluble interleukin (IL)-6 receptor and IL-6 receptor expression on CD4+ T cells in patients with chronic hepatitis B. Int J Infect Dis. 2011;15(4):e267-e271.
43	H Debiec, V Guigonis, BAA Mougenot, et al. Antenatal membranous glomerulonephritis with vascular injury induced by anti-neutral endopeptidase antibodies: toward new concepts in the pathogenesis of glomerular diseases. J Am Soc Nephrol. 2003;14(1):S27-S32.
44	NM Tomas, LH Beck, C Meyer-Schwesinger, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277-2287.
45	M Fresquet, SJ Rhoden, TA Jowitt, et al. Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain. J Autoimmun. 2020;106:102308.
46	S Sethi, B Madden. Mapping antigens of membranous nephropathy: almost there. Kidney Int. 2023;103(3):469-472.
47	S Sethi. New ‘antigens’ in membranous nephropathy. J Am Soc Nephrol. 2021;32(2):268-278.
48	S Sethi, H Debiec, B Madden, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97(1):163-174.
49	S Sethi, BJ Madden, H Debiec, et al. Exostosin 1/Exostosin 2-associated membranous nephropathy. J Am Soc Nephrol. 2019;30(6):1123-1136.
50	S Sethi, H Debiec, B Madden, et al. Semaphorin 3B–associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 2020;98(5):1253-1264.
51	S Sethi, B Madden, H Debiec, et al. Protocadherin 7-associated membranous nephropathy. J Am Soc Nephrol. 2021;32(5):1249-1261.
52	TN Caza, SI Hassen, M Kuperman, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int. 2021;100(1):171-181.
53	S Sethi, B Madden, M Casal Moura, et al. Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1. J Am Soc Nephrol. 2022;33(5):1033-1044.
54	S Sethi, B Madden, M Casal Moura, et al. Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor. J Am Soc Nephrol. 2023;34(3):374-384.
55	EYM Chung, YM Wang, K Keung, et al. Membranous nephropathy: clearer pathology and mechanisms identify potential strategies for treatment. Front Immunol. 2022;13:1036249.
56	TN Caza, AJ Storey, SI Hassen, et al. Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry. Kidney Int. 2023;103(3):593-606.
57	TN Caza, SI Hassen, DJ Kenan, et al. Transforming growth factor beta receptor 3 (TGFBR3)-associated membranous nephropathy. Kidney360. 2021;2(8):1275-1286.
58	LF Al-Rabadi, T Caza, C Trivin-Avillach, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy. J Am Soc Nephrol. 2021;32(7):1666-1681.
59	M Le Quintrec, M Teisseyre, N Bec, et al. Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. Kidney Int. 2021;100(6):1240-1249.
60	SA Bobart, S Tehranian, S Sethi, et al. A target antigen-based approach to the classification of membranous nephropathy. Mayo Clin Proc. 2021;96(3):577-591.
61	S Sethi, LH Beck, RJ Glassock, et al. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int. 2023;104(6):1092-1102.
62	Z Dong, H Dai, W Liu, et al. Exploring the differences in molecular mechanisms and key biomarkers between membranous nephropathy and lupus nephritis using integrated bioinformatics analysis. Front Genet. 2022;12:770902.
63	S Sethi, M Casal Moura, B Madden, et al. Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use. Kidney Int. 2023;104(2):343-352.
64	R Hausmann, M Grepl, V Knecht, MJ Moeller. The glomerular filtration barrier function: new concepts. Curr Opin Nephrol Hypertens. 2012;21(4):441-449.
65	R Bronstein, J Pace, Y Gowthaman, DJ Salant, SK Mallipattu. Podocyte-parietal epithelial cell interdependence in glomerular development and disease. J Am Soc Nephrol. 2023;34(5):737-750.
66	C Schell, TB Huber. The evolving complexity of the podocyte cytoskeleton. J Am Soc Nephrol. 2017;28(11):3166-3174.
67	CC Lu, GH Wang, J Lu, et al. Role of podocyte injury in glomerulosclerosis. Adv Exp Med Biol. 2019;1165:195-232.
68	L Perico, S Conti, A Benigni, G Remuzzi. Podocyte-actin dynamics in health and disease. Nat Rev Nephrol. 2016;12(11):692-710.
69	P Garg, LB Holzman. Podocytes: gaining a foothold. Exp Cell Res. 2012;318(9):955-963.
70	J Peti-Peterdi, A Sipos. A high-powered view of the filtration barrier. J Am Soc Nephrol. 2010;21(11):1835-1841.
71	A Greka, P Mundel. Cell biology and pathology of podocytes. Annu Rev Physiol. 2012;74:299-323.
72	PL St John, DR Abrahamson. Glomerular endothelial cells and podocytes jointly synthesize laminin-1 and -11 chains. Kidney Int. 2001;60(3):1037-1046.
73	H Jiang, Z Shen, J Zhuang, et al. Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy. Front Immunol. 2023;14:1335936.
74	P Ronco, H Debiec. A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease. Pflugers Arch. 2017;469(7-8):997-1005.
75	S Li, Y Liu, Y He, et al. Podocytes present antigen to activate specific T cell immune responses in inflammatory renal disease. J Pathol. 2020;252(2):165-177.
76	W Coers, E Brouwer, JT Vos, et al. Podocyte expression of MHC class I and II and intercellular adhesion molecule-1 (ICAM-1) in experimental pauci-immune crescentic glomerulonephritis. Clin Exp Immunol. 1994;98(2):279-286.
77	J Reiser, G Von Gersdorff, M Loos, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113(10):1390-1397.
78	CC Yu, A Fornoni, A Weins, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369(25):2416-2423.
79	J Haydak, EU Azeloglu. Role of biophysics and mechanobiology in podocyte physiology. Nat Rev Nephrol. 2024;20(6):371-385.
80	A Squarer, KV Lemley, S Ambalavanan, et al. Mechanisms of progressive glomerular injury in membranous nephropathy. J Am Soc Nephrol. 1998;9(8):1389-1398.
81	H Imai, K Hamai, A Komatsuda, H Ohtani, AB Miura. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int. 1997;51(1):270-276.
82	LH No?l, P Aucouturier, RC Monteiro, JL Preud'Homme, P Lesavre. Glomerular and serum immunoglobulin G subclasses in membranous nephropathy and anti-glomerular basement membrane nephritis. Clin Immunol Immunopathol. 1988;46(2):186-194.
83	P Ronco, H Debiec. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015;385(9981):1983-1992.
84	G Haddad, JM Lorenzen, H Ma, et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1–associated membranous nephropathy. J Clin Invest. 2021;131(5):e140453.
85	DJ Salant, S Belok, MP Madaio, WG Couser. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest. 1980;66(6):1339-1350.
86	H Wang, D Lv, S Jiang, et al. Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction. Cell Death Dis. 2022;13(3):281.
87	M Nagata. Podocyte injury and its consequences. Kidney Int. 2016;89(6):1221-1230.
88	CD Voinescu, M Mozere, G Genovese, et al. A Neanderthal haplotype introgressed into the human genome confers protection against membranous nephropathy. Kidney Int. 2024;105(4):791-798.
89	HC Stanescu, M Arcos-Burgos, A Medlar, et al. Risk HLA-DQA1 and PLA 2 R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364(7):616-626.
90	E Thorsby. A short history of HLA. Tissue Antigens. 2009;74(2):101-116.
91	PT Klouda, EJ Acheson, FS Goldby, et al. Strong association between idiopathic membranous nephropathy and HLA-DRW3. Lancet. 1979;2(8146):770-771.
92	RW Vaughan, MR Tighe, K Boki, et al. An analysis of HLA class II gene polymorphism in British and Greek idiopathic membranous nephropathy patients. Eur J Immunogenet. 1995;22(2):179-186.
93	Z Cui, LJ Xie, FJ Chen, et al. MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy. J Am Soc Nephrol. 2017;28(5):1651-1664.
94	WB Le, JS Shi, T Zhang, et al. HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-related membranous nephropathy. J Am Soc Nephrol. 2017;28(5):1642-1650.
95	M Thiri, K Honda, K Kashiwase, et al. High-density association mapping and interaction analysis of PLA2R1 and HLA regions with idiopathic membranous nephropathy in Japanese. Sci Rep. 2016;6(1):38189.
96	WB Le, JS Shi, Y Fan, SW Gong. HLA alleles and prognosis of PLA2R-related membranous nephropathy. Clin J Am Soc Nephrol. 2021;16(8):1221-1227.
97	F Wang, TT Wang, XW Liang, et al. PLA2R1 and HLA-DQA1 gene variations in idiopathic membranous nephropathy in South China. Ann Acad Med Singapore. 2021;50(1):33-41.
98	R Ramachandran, V Kumar, A Kumar, et al. PLA 2 R antibodies, glomerular PLA 2 R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians. Nephrol Dial Transplant. 2016;31(9):1486-1493.
99	J Lv, W Hou, X Zhou, et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol. 2013;24(8):1323-1329.
100	P Hamilton, K Blaikie, SA Roberts, et al. Membranous nephropathy in the UK Biobank. PLoS One. 2023;18(4):e0281795.
101	L Berchtold, E Letouzé, MP Alexander, et al. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney Int. 2021;99(3):671-685.
102	X Liu, W Xu, C Yu, M Wang, R Liu, R Xie. Associations between m-type phospholipase A2 receptor, human leukocyte antigen gene polymorphisms and idiopathic membranous nephropathy. Bioengineered. 2021;12(1):8833-8844.
103	C Ji, Q Xu, X Bian. Clinical predictive value of phospholipase A2 receptor gene polymorphism combined with subclass of immunoglobulin G in renal tissues for membranous nephropathy. Altern Ther Health Med. 2023;29(7):418-423.
104	H Kaga, A Komatsuda, A Omokawa, et al. Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy. Clin Exp Nephrol. 2018;22(2):275-282.
105	J Lv, W Hou, XJ Zhou, et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol. 2013;24(8):1323-1329.
106	E Hoxha, I Thiele, G Zahner, U Panzer, S Harendza, RAK Stahl. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357-1366.
107	S Kim, HJ Chin, KY Na, et al. Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy. Nephron Clin Pract. 2010;117(3):c253.
108	J Xie, L Liu, N Mladkova, et al. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat Commun. 2020;11(1):1600.
109	MJH Coenen, JM Hofstra, H Debiec, et al. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol. 2013;24(4):677-683.
110	WI Weis, ME Taylor, K Drickamer. The C-type lectin superfamily in the immune system. Immunol Rev. 1998;163:19-34.
111	AJ Day. The C-type carbohydrate recognition domain (CRD) superfamily. Biochem Soc Trans. 1994;22(1):83-88.
112	AS Bomback, AG Gharavi. Can genetics risk-stratify patients with membranous nephropathy? J Am Soc Nephrol. 2013;24(8):1190-1192.
113	KA Miller, DS Siscovick, L Sheppard, et al. Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med. 2007;356(5):447-458.
114	X Xu, G Wang, N Chen, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27(12):3739-3746.
115	JC Pfau, JM Brown, A Holian. Silica-exposed mice generate autoantibodies to apoptotic cells. Toxicology. 2004;195(2-3):167-176.
116	P Zhang, W Huang, Q Zheng, et al. A novel insight into the role of PLA2R and THSD7A in membranous nephropathy. J Immunol Res. 2021;2021:1-12. Yang C, ed.
117	S Agrawal, JJ Zaritsky, A Fornoni, WE Smoyer. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57-70.
118	P Ronco, L Beck, H Debiec, et al. Membranous nephropathy Nat Rev Dis Primer. 2021;7(1):1-23.
119	MA Saleem. Molecular stratification of idiopathic nephrotic syndrome. Nat Rev Nephrol. 2019;15(12):750-765.
120	WG Couser. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997.
121	F Wa, J Rb, E Dp. Membranous glomerulonephritis: long-term serial observations on clinical course and morphology. Kidney Int. 1973;4(1).
122	DT Erwin, JV Donadio, KE Holley. The clinical course of idiopathic membranous nephropathy. Mayo Clin Proc. 1973;48(10):697-712.
123	L Safar-Boueri, A Piya, LH Beck, R Ayalon. Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era. Pediatr Nephrol Berl Ger. 2021;36(1):19-30.
124	RL Luciano, GW Moeckel. Update on the native kidney biopsy: core curriculum 2019. Am J Kidney Dis. 2019;73(3):404-415.
125	J Floege, RJ Johnson, K Gordon, et al. Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney Int. 1992;42(3):573-585.
126	AW Basford, J Lewis, JP Dwyer, AB Fogo. Membranous nephropathy with crescents. J Am Soc Nephrol. 2011;22(10):1804-1808.
127	DJ Salant. Unmet challenges in membranous nephropathy. Curr Opin Nephrol Hypertens. 2019;28(1):70-76.
128	L Seifert, G Zahner, C Meyer-Schwesinger, et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nat Commun. 2023;14(1):473.
129	S Gao, Z Cui, MH Zhao. Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy. J Am Soc Nephrol. 2022;33(9):1742-1756.
130	G Moroni, C Ponticelli. Secondary membranous nephropathy. A narrative review. Front Med. 2020;7:611317.
131	A Chang, O Aneziokoro, SM Meehan, RJ Quigg. Membranous and crescentic glomerulonephritis in a patient with anti-nuclear and anti-neutrophil cytoplasmic antibodies. Kidney Int. 2007;71(4):360-365.
132	J van den Born, LP van den Heuvel, MA Bakker, et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int. 1993;43(2):454-463.
133	GS Markowitz. Membranous glomerulopathy: emphasis on secondary forms and disease variants. Adv Anat Pathol. 2001;8(3):119-125.
134	O Onwuzuligbo, AR Hendricks, J Hassler, K Domanski, C Goto, MTF Wolf. Mercury intoxication as a rare cause of membranous nephropathy in a child. Am J Kidney Dis. 2018;72(4):601-605.
135	AB Fogo, MA Lusco, B Najafian, CE Alpers. AJKD atlas of renal pathology: membranous nephropathy. Am J Kidney Dis. 2015;66(3):e15-17.
136	S Troyanov, L Roasio, M Pandes, AM Herzenberg, DC Cattran. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int. 2006;69(9):1641-1648.
137	A Malvar, V Alberton, B Lococo, et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int. 2020;97(1):156-162.
138	KP Stiles, CM Yuan, EM Chung, RD Lyon, JD Lane, KC Abbott. Renal biopsy in high-risk patients with medical diseases of the kidney. Am J Kidney Dis. 2000;36(2):419-433.
139	P Cluzel, F Martinez, MF Bellin, et al. Transjugular versus percutaneous renal biopsy for the diagnosis of parenchymal disease: comparison of sampling effectiveness and complications. Radiology. 2000;215(3):689-693.
140	Kidney Disease: improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.
141	S Kurasawa, S Kato, T Ozeki, et al. Rationale and design of the Japanese Biomarkers in Nephrotic Syndrome (J-MARINE) study. Clin Exp Nephrol. 2024;28(5):431-439.
142	V Albertazzi, F Fontana, S Giberti, et al. Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up. J Nephrol. 2024;37(2):471-482.
143	SB Ahmad, GB Appel. Antigens, antibodies, and membranous nephropathy: a decade of progress. Kidney Int. 2020;97(1):29-31.
144	SA Bobart, AS De Vriese, AS Pawar, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95(2):429-438.
145	S Ai, X Yan, X Zhao, et al. Malignancy-associated membranous nephropathy: focus on diagnosis and treatment. J Nephrol. 2023;36(8):2355-2363.
146	D Bajcsi, L Bitó, S Turkevi-Nagy, et al. The value of PLA2R antigen and IgG subclass staining relative to anti-PLA2R seropositivity in the differential diagnosis of membranous nephropathy. BMC Nephrol. 2023;24(1):230.
147	I Nieto-Ga?án, I Iturrieta-Zuazo, C Rita, á Carrasco-Sayalero. Revisiting immunological and clinical aspects of membranous nephropathy. Clin Immunol Orlando Fla. 2022;237:108976.
148	HYG Choung, C Moore, TH Le, et al. The clinicopathologic spectrum of membranous nephropathy with lupus-like features. Nephron. 2023;147(7):424-433.
149	S Gupta, RJ Pepper, N Ashman, SB Walsh. Nephrotic syndrome: oedema formation and its treatment with diuretics. Front Physiol. 2018;9:1868.
150	BH Rovin, SG Adler, J Barratt, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):753-779.
151	BH Rovin, SG Adler, J Barratt, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):S1-S276.
152	L Peritore, V Labbozzetta, V Maressa, et al. How to choose the right treatment for membranous nephropathy. Med Kaunas Lith. 2023;59(11):1997.
153	M Duffy, S Jain, N Harrell, N Kothari, AS Reddi. Albumin and furosemide combination for management of edema in nephrotic syndrome: a review of clinical studies. Cells. 2015;4(4):622-630.
154	CC Geddes, DC Cattran. The treatment of idiopathic membranous nephropathy. Semin Nephrol. 2000;20(3):299-308.
155	AE van de Logt, JM Hofstra, JF Wetzels. Pharmacological treatment of primary membranous nephropathy in 2016. Expert Rev Clin Pharmacol. 2016;9(11):1463-1478.
156	JAJG van den Brand, PR van Dijk, JM Hofstra, JFM Wetzels. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol. 2014;25(1):150-158.
157	C Faul, M Donnelly, S Merscher-Gomez, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931-938.
158	K Dahan, H Debiec, E Plaisier, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348-358.
159	C Cantarelli, M Jarque, A Angeletti, et al. A comprehensive phenotypic and functional immune analysis unravels circulating anti–phospholipase A2 receptor antibody secreting cells in membranous nephropathy patients. Kidney Int Rep. 2020;5(10):1764-1776.
160	A Kuroki, M Iyoda, T Shibata, T Sugisaki. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005;68(1):302-310.
161	TW Kuijpers, RJ Bende, PA Baars, et al. CD20 deficiency in humans results in impaired T cell–independent antibody responses. J Clin Invest. 2010;120(1):214-222.
162	TF Tedder, M Streuli, SF Schlossman, H Saito. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci. 1988;85(1):208-212.
163	FC Fervenza, RS Abraham, SB Erickson, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010;5(12):2188-2198.
164	Y Takahashi, Y Ikezumi, A Saitoh. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes. Nephrology. 2017;22(1):49-57.
165	SJ Barbour, FC Fervenza, D Induruwage, et al. Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy. Clin J Am Soc Nephrol. 2023;18(10):1283-1293.
166	DJ Salant. Does epitope spreading influence responsiveness to rituximab in PLA2R-associated membranous nephropathy? Clin J Am Soc Nephrol. 2019;14(8):1122-1124.
167	R Ramachandran, R Prabakaran, G Priya, et al. Immunosuppressive therapy in primary membranous nephropathy with compromised renal function. Nephron. 2022;146(2):138-145.
168	P Chen, M Mao, C Wang, et al. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: a single-centre experience. Front Endocrinol. 2023;14:1044782.
169	FC Fervenza, GB Appel, SJ Barbour, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36-46.
170	K Dahan, C Johannet, E Esteve, E Plaisier, H Debiec, P Ronco. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody. Kidney Int. 2019;95(1):233-234.
171	N Hanset, E Esteve, E Plaisier, et al. Rituximab in patients with phospholipase A2 receptor–associated membranous nephropathy and severe CKD. Kidney Int Rep. 2020;5(3):331-338.
172	P Cravedi, MC Sghirlanzoni, M Marasà, A Salerno, G Remuzzi, P Ruggenenti. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol. 2011;33(5):461-468.
173	L Deng, G Xu. Update on the application of monoclonal antibody therapy in primary membranous nephropathy. Drugs. 2023;83(6):507-530.
174	AL Gagez, G Cartron. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 2014;26(5):484-491.
175	CL Freeman, LH Sehn. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29-45.
176	B Basu, A Angeletti, B Islam, GM Ghiggeri. New and old anti-CD20 monoclonal antibodies for nephrotic syndrome. Where we are? Front Immunol. 2022;13:805697.
177	E Ahmadian, SMH Khatibi, SZ Vahed, M Ardalan. Novel treatment options in rituximab-resistant membranous nephropathy patients. Int Immunopharmacol. 2022;107:108635.
178	L Zand, FC Fervenza. Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy. Clin Kidney J. 2023;16(9):1420-1425.
179	E M?ssner, P Brünker, S Moser, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.
180	N Klomjit, FC Fervenza, L Zand. Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases. Am J Kidney Dis. 2020;76(6):883-888.
181	S Sethi, S Kumar, K Lim, SC Jordan. Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep. 2020;5(9):1515-1518.
182	C Barrett, LC Willcocks, RB Jones, et al. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant. 2020;35(4):599-606.
183	E Bryer, C DeStefano, D Kazandjian. Current and prospective antibody-based therapies in multiple myeloma. Semin Oncol. 2022;49(1):41-47.
184	HA Blair, ST Duggan. Belimumab: a review in systemic lupus erythematosus. Drugs. 2018;78(3):355-366.
185	W Stohl, A Schwarting, M Okada, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two–week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016-1027.
186	L Zhang, H Jin, D Wang, Y Wang. Case report: successful treatment of refractory membranous nephropathy with telitacicept. Front Immunol. 2023;14:1268929.
187	Y Li, H Liu, H Yan, J Xiong. Research advances on targeted-Treg therapies on immune-mediated kidney diseases. Autoimmun Rev. 2023;22(2):103257.
188	E Hoxha, L Reinhard, RAK Stahl. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol. 2022;18(7):466-478.
189	J Weinmann-Menke, S Holtz, D Sollinger, et al. Treatment of membranous nephropathy in patients with THSD7A antibodies using immunoadsorption. am j kidney dis. 2019;74(6):849-852.
190	P Hamilton, D Kanigicherla, P Hanumapura, et al. Peptide GAM immunoadsorption in anti-PLA2 R positive autoimmune membranous nephropathy. The PRISM trial. J Clin Apheresis. 2022;37(1):40-53.
191	SJ Schuster, J Svoboda, EA Chong, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545-2554.
192	JH Park, I Rivière, M Gonen, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449-459.
193	SMS K?llner, L Seifert, G Zahner, NM Tomas. Strategies towards antigen-specific treatments for membranous nephropathy. Front Immunol. 2022;13:822508.
194	H Miao, Y ni Wang, W Su, et al. Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1/β-catenin pathway. Acta Pharmacol Sin. 2024;45(1):137-149.
195	J Shortt, DH Oh, SS Opat. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013;368(1):90-92.
196	DK Perry, JM Burns, HS Pollinger, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2009;9(1):201-209.
197	C Hartono, M Chung, SF Kuo, SV Seshan, T Muthukumar. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. J Nephrol. 2014;27(1):103-106.
198	AS Geara, V Bhoj, JJ Hogan. Bortezomib treatment for refractory PLA2R-positive membranous nephropathy. Glomerular Dis. 2021;1(1):40-43.
199	S Salhi, D Ribes, M Colombat, F Fortenfant, S Faguer. Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy. Kidney Int. 2021;100(3):708-709.
200	F Caravaca-Fontán, F Yandian, FC Fervenza. Future landscape for the management of membranous nephropathy. Clin Kidney J. 2023;16(8):1228-1238.
201	SK Khaled, K Claes, YT Goh, et al. Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy. J Clin Oncol. 2022;40(22):2447-2457.
202	J Müller-Deile, L Schiffer, M Hiss, H Haller, M Schiffer. A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest. 2015;45(12):1260-1269.
203	BK Mahmoodi, MK ten Kate, F Waanders, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117(2):224-230.
204	RJ Glassock. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007;18(8):2221-2225.
205	R Lin, G McDonald, T Jolly, A Batten, B Chacko. A systematic review of prophylactic anticoagulation in nephrotic syndrome. Kidney Int Rep. 2020;5(4):435-447.
206	T Lee, VK Derebail, AV Kshirsagar, et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int. 2016;89(5):1111-1118.
207	X Gao, Y Liu, Q He, X Shen. Cerebral venous sinus thrombosis in nephrotic syndrome. Kidney Int. 2022;101(6):1303.
208	KI Greenberg, MJ Choi. Understanding hypercoagulability with nephrotic syndrome: how the clot thickens. Clin J Am Soc Nephrol. 2023;18(2):149-151.
209	E Abdelghani, AP Waller, KJ Wolfgang, et al. Exploring the role of antithrombin in nephrotic syndrome-associated hypercoagulopathy: a multi-cohort study and meta-analysis. Clin J Am Soc Nephrol. 2023;18(2):234-244.
210	A Gigante, F Di Mario, A Pierucci, et al. Kidney disease and venous thromboembolism: does being woman make the difference? Eur J Intern Med. 2017;39:18-23.
211	S Lionaki, VK Derebail, SL Hogan, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(1):43-51.
212	BA Kerlin, R Ayoob, WE Smoyer. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(3):513-520.
213	SJ Barbour, A Greenwald, O Djurdjev, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81(2):190-195.
214	M Cremoni, V Brglez, S Perez, et al. Th17-immune response in patients with membranous nephropathy is associated with thrombosis and relapses. Front Immunol. 2020;11:574997.
215	P Kaur, A Prabhahar, D Pal, et al. IL-23/IL-17 in a paradoxical association with primary membranous nephropathy. Inflammation. 2024. doi:. Online ahead of print.
216	A Angeletti, P Migliorini, M Bruschi, et al. Anti-alpha enolase multi-antibody specificity in human diseases. Clinical significance and molecular mechanisms. Autoimmun Rev. 2021;20(12):102977.
217	V Papayannopoulos. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134-147.
218	BA Kerlin, AP Waller, R Sharma, MA Chanley, MT Nieman, WE Smoyer. Disease severity correlates with thrombotic capacity in experimental nephrotic syndrome. J Am Soc Nephrol. 2015;26(12):3009-3019.
219	F Caravaca-Fontán, GM Fernández-Juárez, J Floege, et al. The management of membranous nephropathy-an update. Nephrol Dial Transplant. 2022;37(6):1033-1042.
220	JM Hofstra, JFM Wetzels. Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy? Kidney Int. 2016;89(5):981-983.
221	DJ Sexton, DG de Freitas, MA Little, et al. Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome. Kidney Int Rep. 2018;3(4):784-793.
222	ML Reynolds, PH Nachman, MJ Mooberry, DJ Crona, VK Derebail. Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. J Nephrol. 2019;32(4):669-672.
223	VK Derebail, MN Rheault, BA Kerlin. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2020;97(4):664-675.
224	N Polanco, E Gutiérrez, A Covarsí, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol JASN. 2010;21(4):697-704.
225	J Carboni, E Thomas, DS Gipson, et al. Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndrome. Pediatr Nephrol Berl Ger. 2024. doi:. Online ahead of print.
226	ND Vaziri. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41-52.
227	L Dong, YQ Li, SM Guo, G Xu, W Wei, M Han. Hypercholesterolemia correlates with glomerular phospholipase A2 receptor deposit and serum anti-phospholipase A2 receptor antibody and predicts proteinuria outcome in idiopathic membranous nephropathy. Front Immunol. 2022;13:905930.
228	S Feng, X Zhao, Y Wang, Y Wang, G Chen, S Zhang. Autosomal recessive hypercholesterolemia caused by a novel LDLRAP1 variant and membranous nephropathy in a chinese girl: a case report. Front Cardiovasc Med. 2022;9:811317.
229	P Zou, H Li, J Cai, Z Chen, C Li, X Li. Statins can benefit patients with primary membranous nephropathy on venous thromboembolism. Ren Fail. 2021;43(1):302-306.
230	A Thompson, DC Cattran, M Blank, PH Nachman. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol JASN. 2015;26(12):2930-2937.
231	N Wouk. End-stage renal disease: medical management. Am Fam Physician. 2021;104(5):493-499.
232	S Voora, DB Adey. Management of kidney transplant recipients by general nephrologists: core curriculum 2019. Am J Kidney Dis. 2019;73(6):866-879.
233	C Garofalo, C Ruotolo, C Annoiato, et al. Sustained recovery of kidney function in patients with ESKD under chronic dialysis treatment: systematic review and meta-analysis. Nutrients. 2023;15(7):1595.
234	T Chen, VW Lee, DC Harris. When to initiate dialysis for end-stage kidney disease: evidence and challenges. Med J Aust. 2018;209(6):275-279.
235	X Jia, X Tang, Y Li, D Xu, P Moreira. Update of dialysis initiation timing in end stage kidney disease patients: is it a resolved question? A systematic literature review. BMC Nephrol. 2023;24(1):162.
236	CY Hsu, RV Parikh, LN Pravoverov, et al. Implication of trends in timing of dialysis initiation for incidence of end-stage kidney disease. JAMA Intern Med. 2020;180(12):1647-1654.
237	Y Qin, Z Yu, H Wu, et al. Prognostic factors affecting long-term outcomes in patients with concurrent IgA nephropathy and membranous nephropathy. Heliyon. 2024;10(1):e23436.
238	LJ Reichert, RA Koene, JF Wetzels. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis. 1998;31(1):1-11.
239	Y Pei, D Cattran, C Greenwood. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 1992;42(4):960-966.
240	JAJG van den Brand, JM Hofstra, JFM Wetzels. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(12):2846-2853.
241	JAJG van den Brand, JM Hofstra, JFM Wetzels. Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(8):1242-1248.
242	W Liu, G Huang, H Rui, et al. Course monitoring of membranous nephropathy: both autoantibodies and podocytes require multidimensional attention. Autoimmun Rev. 2022;21(2):102976.
243	AE Logt, J Justino van de,, CH Vink, et al. Anti-PLA2R1 antibodies as prognostic biomarker in membranous nephropathy. Kidney Int Rep. 2021;6(6):1677-1686.
244	S Kant, A Kronbichler, P Sharma, D Geetha. Advances in understanding of pathogenesis and treatment of immune-mediated kidney disease: a review. Am J Kidney Dis. 2022;79(4):582-600.
245	S Troyanov, CA Wall, JA Miller, JW Scholey, DC Cattran. Toronto Glomerulonephritis Registry Group. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004;66(3):1199-1205.